https://scholars.lib.ntu.edu.tw/handle/123456789/548839
標題: | Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus | 作者: | CHAO LUN LAI Chou H.-W. KIN-WEI CHAN Lai M.-S. |
公開日期: | 2015 | 出版社: | Elsevier Inc. | 卷: | 115 | 期: | 5 | 起(迄)頁: | 619-624 | 來源出版物: | American Journal of Cardiology | 摘要: | We performed this population-based study to investigate the effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes. From the Taiwan National Health Insurance Pay-for-Performance program for diabetes mellitus database, 2006 to 2009, type 2 diabetic patients aged 40 to 100 years with the first prescription of atorvastatin or rosuvastatin were identified. All the data were linked to the National Health Insurance claims database, 2000 to 2010, to construct longitudinal health care data. The Modification of Diet in Renal Disease equation was used to calculate the estimated glomerular filtration rate (eGFR), and the eGFRs between baseline and the end of follow-up (maximum 2 years) were compared. Totally, 3,601 new users of atorvastatin and 1,968 new users of rosuvastatin were included. The median follow-up was 238 days in atorvastatin users and 210 days in rosuvastatin users. The eGFR at baseline was 72.3 ± 25.9 ml/min/1.73 m2 in atorvastatin users and 73.7 ± 27.3 ml/min/1.73 m2 in rosuvastatin users. In both statin groups, we found no significant change in eGFR (+0.1 ml/min/1.73 m2, 95% confidence interval -0.4 to 0.7, p = 0.62 in atorvastatin users; -0.1 ml/min/1.73 m2, 95% confidence interval -0.8 to 0.6, p = 0.77 in rosuvastatin users). In conclusion, neither treatment with atorvastatin nor rosuvastatin was associated with a significant change of renal function in type 2 diabetic patients. ? 2015 Elsevier Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923047363&doi=10.1016%2fj.amjcard.2014.12.009&partnerID=40&md5=31a9fdd5fd8ea777c237adf0ae6b966e https://scholars.lib.ntu.edu.tw/handle/123456789/548839 |
ISSN: | 0002-9149 | DOI: | 10.1016/j.amjcard.2014.12.009 | SDG/關鍵字: | acetylsalicylic acid; allopurinol; aminoglycoside; angiotensin receptor antagonist; atorvastatin; cephalosporin derivative; dipeptidyl carboxypeptidase inhibitor; histamine H1 receptor antagonist; loop diuretic agent; nonsteroid antiinflammatory agent; paracetamol; penicillin derivative; proton pump inhibitor; quinolone derivative; rosuvastatin; sulfonamide; thiazide diuretic agent; atorvastatin; fluorobenzene; heptanoic acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; pyrimidine derivative; pyrrole derivative; rosuvastatin; sulfonamide; acute kidney failure; adult; aged; Article; chronic kidney disease; cohort analysis; confidence interval; controlled study; data base; diabetic patient; drug efficacy; drug safety; estimated glomerular filtration rate; female; follow up; glomerulus filtration rate; health care; health program; human; kidney function; longitudinal study; major clinical study; male; middle aged; national health insurance; non insulin dependent diabetes mellitus; prescription; priority journal; retrospective study; Taiwan; treatment duration; treatment outcome; Asian continental ancestry group; China; complication; drug effects; ethnology; non insulin dependent diabetes mellitus; pathophysiology; physiology; very elderly; Adult; Aged; Aged, 80 and over; Asian Continental Ancestry Group; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。